• Cynata Therapeutics receives $1.7m R&D Tax Incentive Refund for 2024/2025 financial year
• Refund enables further investment in Cynata's cell therapy product pipeline
• R&D Tax Incentive is an important Australian Government program supporting research and development

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has received a $1,711,618 R&D Tax Incentive Refund for the 2024/2025 financial year. The R&D Tax Incentive is an important Australian Government program that encourages companies to engage in research and development benefiting Australia by providing a tax offset for eligible activities such as the development of Cynata's unique and proprietary Cymerus™ therapeutic mesenchymal stromal cell (MSC) products. The refund will enable Cynata to further invest resources towards progressing its broad and advanced cell therapy product pipeline. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing, including a Phase 2 trial of CYP-001 in GvHD, a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation, and a Phase 3 trial of CYP-004 in osteoarthritis. Cynata has also demonstrated the utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.